A New Dawn in Cannabinoid Medicine

We are an innovative pharmaceutical company specializing in the development of medicines manufactured from cannabinoid and “cannabinoid-like” molecules.

We have an interest is botanically derived cannabis-based medicines and also single molecule medicines. We also have an interest in producing cannabinoid and “cannabinoid-like” active ingredients for other business sectors, such as cosmetic ingredients.

We are developing treatments for a variety of clinical indications, with a focus on conditions where there is a high unmet medical need. Specifically, we are looking to develop our products:

  • from cannabis-based extracts
  • from single chemically-synthesized molecules inspired by single components

UNMET MEDICAL NEEDS

INNOVATION

molecules_126036009-min
AIMING FOR BETTER
TREATMENTS THROUGH INNOVATION

Our approach will allow us to not only build on the intellectual property that we currently hold, but to build on the knowledge and experience that we have gained from years of research and development experience of cannabis-based medicines at GW Pharmaceuticals (which was sold to Jazz Pharmaceuticals in May 2021 for $7.2 billion US dollars). We are focusing on 2 main clinical indications with 2 separate product types:

  • Bladder Pain Syndrome
  • Treatment-resistant focal seizures in adults